Prof. Dr. Yılmaz ÇAKALOĞLU

Yayın Ağı

Makaleler 23

1. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey

AKARCA U. S., AKHAN O., Bilgic S., BOZKURT M. F., Cantasdemir M., Cermik T. F., et al.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY , cilt.27, sa.6, ss.732-739, 2021 (SCI-Expanded)

2. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta

Wranke A., Hardtke S., Heidrich B., Dalekos G., YALÇIN K., Tabak F., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.27, sa.12, ss.1359-1368, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma

3. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

İDİLMAN R., DEMİR M., ALADAĞ M., Erol C., Cavus B., Iliaz R., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.26, sa.6, ss.666-674, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma

4. Durability of sustained virologic response in chronic hepatitis C

UYANIKOĞLU A., Kaymakoglu S., Danalioglu A., Akyuz F., Ermis F., Pinarbasi B., et al.

Gut and Liver , cilt.7, sa.4, ss.458-461, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

5. Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

Sonneveld M. J., Wong V. W., Woltman A. M., Wong G. L. H., Cakaloglu Y., Zeuzem S., et al.

GASTROENTEROLOGY , cilt.142, sa.3, ss.513-521, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

6. Anticoagulant therapy and Budd-Chiari syndrome: Is it successful?

Akyuz F., Cakaloglu Y., Pinarbasi B., Demir K., Akyuz U., Ozdil S., et al.

Hepato-Gastroenterology , cilt.58, ss.900-903, 2011 (SCI-Expanded)

7. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis

Zachou K., Yurdaydin C., Drebber U., Dalekos G. N., Erhardt A., Cakaloglu Y., et al.

LIVER INTERNATIONAL , cilt.30, sa.3, ss.430-437, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma

8. Electron microscopic findings in non-alcoholic fatty liver disease: Is there a difference between hepatosteatosis and steatohepatitis?

Ahishali E., Demir K., Ahishali B., Akyuz F., Pinarbasi B., Poturoglu S., et al.

Journal of Gastroenterology and Hepatology (Australia) , cilt.25, sa.3, ss.619-626, 2010 (SCI-Expanded)

9. The quality of life in hemodialysis patients with chronic hepatitis C virus infection

Akyuz F., Besisik F., Pinarbasi B., Demir K., Kaymakoglu S., Cakaloglu Y., et al.

Turkish Journal of Gastroenterology , cilt.20, sa.4, ss.243-246, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

10. Are acquired hepatocerebral degeneration and hepatic myelopathy reversible?

Pinarbasi B., Kalymakoglu S., Matur Z., Akyuz F., Demir K., Besisik F., et al.

Journal of clinical gastroenterology , cilt.43, sa.2, ss.176-81, 2009 (SCI-Expanded)

11. 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

Liaw Y., Gane E., Leung N., Zeuzem S., Wang Y., Lai C. L., et al.

GASTROENTEROLOGY , cilt.136, sa.2, ss.486-495, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

12. Intestinal metaplasia in portal hypertensive gastropathy: A frequent pathology

Ibrisim D., Cevikbas U., Akyuz F., Poturoglu S., Ahishali E., Gulluoglu M., et al.

European Journal of Gastroenterology and Hepatology , cilt.20, sa.9, ss.874-880, 2008 (SCI-Expanded)

13. Prevalence and clinical significance of SEN-H virus in chronic hepatitis B, C and delta infections in Turkey

Cakaloglu Y., Akyuez F., Bozaci M., Ibrisim D., Pinarbasi B., Demir K., et al.

Turkish Journal of Gastroenterology , cilt.19, sa.2, ss.104-108, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

14. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease

Akyuez F., Demir K., Oezdil S., Aksoy N., Poturoglu S., Ibrisim D., et al.

Digestive Diseases and Sciences , cilt.52, sa.9, ss.2359-2367, 2007 (SCI-Expanded)

15. Pegylatedd interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B

Kaymakoglu S., Oguz D., Gur G., Gurel S., Tankurt E., Ersoz G., et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , cilt.51, sa.8, ss.3020-3022, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

16. Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B

Kaymakoglu S., Danalioglu A., Demir K., Karaca C., Akyuz F., Onel D., et al.

Digestive Diseases and Sciences , cilt.52, sa.3, ss.727-731, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

17. PERNICIOUS ANEMIA ASSOCIATED WITH CRYPTOGENIC CIRRHOSIS

Cosan F., Pinarbasi B., Ibrisim D., GÜLLÜOĞLU M., DEMİR K., KAYMAKOĞLU S., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , cilt.70, sa.4, ss.107-110, 2007 (ESCI)

18. Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy

Akyuz F., Kaymakoglu S., Demir K., Aksoy N., Karaca C., Danalioglu A., et al.

Acta Gastro-Enterologica Belgica , cilt.70, sa.1, ss.20-24, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

19. Modelling of early viral kinetics and pegylated interferon-alpha 2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B

ter Borg M. J., Hansen B. E., Herrmann E., Zeuzem S., Cakaloglu Y., Karayalcin S., et al.

ANTIVIRAL THERAPY , cilt.12, sa.8, ss.1285-1294, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma

20. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient

Ibrisim D., Cakaloglu Y., Akyuz F., Karadag A., Ozdil S., Besisik F., et al.

Scandinavian Journal of Gastroenterology , cilt.41, sa.7, ss.862-865, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma

21. Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels

Akyuz F., Polat N., Kaymakoglu S., Aksoy N., Demir K., Besisik F., et al.

World Journal of Gastroenterology , cilt.11, sa.45, ss.7188-7191, 2005 (SCI-Expanded) Sürdürülebilir Kalkınma

22. Sexual transmission of HCV between spouses

Tahan V., Karaca C., Yildirim B., Bozbaş A., Ozaras R., Demir K., et al.

American Journal of Gastroenterology , cilt.100, sa.4, ss.821-824, 2005 (SCI-Expanded) Sürdürülebilir Kalkınma

23. Miconazole induced acute hepatitis and sexual intercourse!

Beşişik F., Dinçer D., DEMİR K., KAYMAKOĞLU S., Çakalǒglu Y., Çevikbaş U., et al.

Turkish Journal of Gastroenterology , cilt.12, sa.1, ss.59-63, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 12

1. Early prediction of response to peginterferon for HBeAg-positive chronic hepatitis B using HBsAg levels at week 4 and week 8 of therapy

Sonneveld M. J., Brouwer W. P., Zeuzem S., Cakaloglu Y., Tabak F., Simon K., et al.

66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri) Sürdürülebilir Kalkınma

2. "Normal" Serum ALT/AST Level in Turkish Population

Karasu Z., Tozun N., İDİLMAN R., ÖZDOĞAN O. C., Kaymakoglu S., Cakaloglu Y., et al.

66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62

3. PEGINTERFERON TREATMENT REDUCES INTRAHEPATIC HBSAG AND HBCAG EXPRESSION IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: RELATION TO SERUM HBSAG DECLINE AND LONG-TERM RESPONSE

Rijckborst V., Zondervan P. E., Cakaloglu Y., Raptopoulou-Gigi M. P., Tabak F., Akdogan M., et al.

62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 4 - 08 Kasım 2011, cilt.54 Sürdürülebilir Kalkınma

4. EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY

Rijckborst V., Hansen B. E., Ferenci P., Brunetto M. R., Tabak F., Cakaloglu Y., et al.

61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 29 Ekim - 02 Kasım 2010, cilt.52

5. PEGINTERFERON ALFA-2B INDUCED HBSAG DECLINE IS DURABLE THROUGH LONG-TERM FOLLOW-UP IN HBEAG-POSITIVE PATIENTS

Sonneveld M. J., Rijckborst V., Cakaloglu Y., Simon K., Trojan J., Tabak F., et al.

61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 29 Ekim - 02 Kasım 2010, cilt.52

6. A NATIONWIDE PREVALENCE STUDY AND RISK FACTORS FOR HEPATITIS A, B, C AND D INFECTIONS IN TURKEY

Tozun N., ÖZDOĞAN O. C., Cakaloglu Y., İDİLMAN R., Karasu Z., AKARCA U. S., et al.

61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 29 Ekim - 02 Kasım 2010, cilt.52, (Özet Bildiri) Sürdürülebilir Kalkınma

7. MUTATIONS IN THE PRECORE AND BASAL CORE PROMOTER REGIONS DO NOT INFLUENCE RESPONSIVENESS TO PEGYLATED INTERFERON ALFA-2A TREATMENT FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B

Rijckborst V., Hansen B. E., ter Borg M., Cakaloglu Y., Ferenci P., Tabak F., et al.

60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 30 Ekim - 03 Kasım 2009, cilt.50, (Özet Bildiri) Sürdürülebilir Kalkınma

8. 48 WEEKS OF PEGINTERFERON ALFA-2A ALONE OR IN COMBINATION WITH RIBAVIRIN FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B: ADDITION OF RIBAVIRIN DOES NOT IMPROVE RESPONSE RATES

Janssen H. L., Rijckborst V., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M., et al.

59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Kostarika, 31 Ekim - 04 Kasım 2008, cilt.48, (Özet Bildiri) Sürdürülebilir Kalkınma

9. BASELINE ALT LEVELS BUT NOT HDV-RNA LEVELS ARE ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT OF DELTA HEPATITIS: DATA FROM THE HIDIT-1 TRIAL

Wedemeyer H., Yurdaydin C., Zachou K., Erhardi A., Cakaloglu Y., YALÇIN K., et al.

59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San-Francisco, Kostarika, 31 Ekim - 04 Kasım 2008, cilt.48, (Özet Bildiri) Sürdürülebilir Kalkınma

10. Sustained HBeAg and HBsAg loss after longterm follow-up of HBeAg positive patients treated with peginterferon alpha-2B

Buster E. H., Flink H. J., Cakaloglu Y., Simon C., Trojan J., Tabak F., et al.

58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 2 - 06 Kasım 2007, cilt.46, (Özet Bildiri)

11. Combined or monotherapy, which is better in AntiHBe (+) chronic hepatitis B ?

Danalioglu A., KAYMAKOĞLU S., Cakaloglu Y., DEMİR K., AKYÜZ F., Aksoy N., et al.

Digestive Disease Week 2003 Meeting/104th Annual Meeting of the American-Gastroenterological-Association, ORLANDO, FLORIDA, 17 - 22 Mayıs 2003, cilt.124, (Özet Bildiri)

12. Autoimmune hepatitis; What factors predict the response to combination therapy of azathioprine plus steroid

Kavmakoglu S., DEMİR K., Danalioglu A., AKYÜZ F., Durakoglu Z., Karaca C., et al.

Digestive Disease Week 2003 Meeting/104th Annual Meeting of the American-Gastroenterological-Association, ORLANDO, FLORIDA, 17 - 22 Mayıs 2003, cilt.124, (Özet Bildiri) Sürdürülebilir Kalkınma

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

938

H-İndeks (WoS)

Atıf (Scopus)

1001

H-İndeks (Scopus)

BM Sürdürülebilir Kalkınma Amaçları